Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ZYRTEC ALLERGY versus KETOTIFEN FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ZYRTEC ALLERGY versus KETOTIFEN FUMARATE.
CHILDREN'S ZYRTEC ALLERGY vs KETOTIFEN FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a selective antagonist of peripheral H1 histamine receptors, inhibiting histamine-mediated allergic and inflammatory responses.
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
5 mg (1 tablet or 5 mL oral solution) once daily; dosing frequency may be increased to 10 mg once daily (2 tablets or 10 mL) for more severe symptoms.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
None Documented
None Documented
Terminal half-life 8.5–10.5 hours in children 2–5 years; 9–11 hours in children 6–12 years; 8–9 hours in adults. Clinically, supports once-daily dosing.
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Primarily renal (60% unchanged) via tubular secretion; 40% metabolized in liver to inactive metabolites excreted in urine; <1% fecal.
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Category C
Category A/B
Antihistamine
Antihistamine / Mast Cell Stabilizer